Q-omics provides the consensus-scored ZNF214 profile across patient tissues and cancer cell-line models. ZNF214 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF214 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, ZNF214 RNA expression shows 19,698 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where ZNF214 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF214 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF214 survival associations across molecular data types. ZNF214 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF214 RNA expression–survival associations across cancer types. High ZNF214 expression shows unfavorable associations in KICH and LAML, but favorable associations in KIRC, BRCA, MESO and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF214 RNA expression.
This table summarizes ZNF214 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF214. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF214 shows lower tumor expression in KICH, UCEC, THCA and LUSC and higher tumor expression in COAD and CHOL. The KICH box plot shows higher ZNF214 RNA expression in normal versus tumor tissue (log2 FC = −1.405, t-test p < 0.001).
This table shows molecular features associated with ZNF214 in patient tissues and cancer cell lines. In patient samples, ZNF214 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF214 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
